Poor prognosis acute myelogenous leukemia

3 - Biological and molecular biological changes during remission induction therapy

E. Devemy, Biaoru Li, M. Tao, E. Horvath, H. Chopra, L. Fisher, J. Nayini, S. Creech, P. Venugopal, J. Yang, C. Kaspar, W. T. Hsu, H. D. Preisler

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

This is the third paper in a series which describes a new remission induction regimen for patients with 'poor prognosis' acute myelogenous leukemia (AML). Twenty-four patients were treated with two one day pulses of chemotherapy separated by 96 h. Each pulse consisted of two doses of cytarabine and a single dose of mitoxantrone. Amifostine was administered three times a week after the second pulse of chemotherapy until treatment outcome became known. The first paper described the outcome of treatment while the second described the relationship of treatment outcome to the pretherapy characteristics of the leukemia. This paper describes the changes in the leukemia cells which occur during remission induction therapy. While only a limited number of specimens were available for each post treatment study, the studies demonstrated a profound fall in blood counts, BM cellularity, and telomerase activity in leukemia cells after pulse # 1 of treatment. This fall was usually accompanied by a coordinate rise in IL6, TNFα, and IL1β transcripts within the AML cells which survived chemotherapy. High levels of telomerase activity in the day 5 marrow was correlated with high levels of IL1β transcripts which in turn were associated with treatment failure ascribable to resistant disease.

Original languageEnglish (US)
Pages (from-to)783-791
Number of pages9
JournalLeukemia Research
Volume25
Issue number9
DOIs
StatePublished - Jan 1 2001

Fingerprint

Remission Induction
Acute Myeloid Leukemia
Leukemia
Telomerase
Drug Therapy
Amifostine
Mitoxantrone
Cytarabine
Treatment Failure
Interleukin-6
Therapeutics
Bone Marrow

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

Poor prognosis acute myelogenous leukemia : 3 - Biological and molecular biological changes during remission induction therapy. / Devemy, E.; Li, Biaoru; Tao, M.; Horvath, E.; Chopra, H.; Fisher, L.; Nayini, J.; Creech, S.; Venugopal, P.; Yang, J.; Kaspar, C.; Hsu, W. T.; Preisler, H. D.

In: Leukemia Research, Vol. 25, No. 9, 01.01.2001, p. 783-791.

Research output: Contribution to journalArticle

Devemy, E, Li, B, Tao, M, Horvath, E, Chopra, H, Fisher, L, Nayini, J, Creech, S, Venugopal, P, Yang, J, Kaspar, C, Hsu, WT & Preisler, HD 2001, 'Poor prognosis acute myelogenous leukemia: 3 - Biological and molecular biological changes during remission induction therapy', Leukemia Research, vol. 25, no. 9, pp. 783-791. https://doi.org/10.1016/S0145-2126(01)00032-7
Devemy, E. ; Li, Biaoru ; Tao, M. ; Horvath, E. ; Chopra, H. ; Fisher, L. ; Nayini, J. ; Creech, S. ; Venugopal, P. ; Yang, J. ; Kaspar, C. ; Hsu, W. T. ; Preisler, H. D. / Poor prognosis acute myelogenous leukemia : 3 - Biological and molecular biological changes during remission induction therapy. In: Leukemia Research. 2001 ; Vol. 25, No. 9. pp. 783-791.
@article{a64dd616293d44ffb55ebdfca3273c27,
title = "Poor prognosis acute myelogenous leukemia: 3 - Biological and molecular biological changes during remission induction therapy",
abstract = "This is the third paper in a series which describes a new remission induction regimen for patients with 'poor prognosis' acute myelogenous leukemia (AML). Twenty-four patients were treated with two one day pulses of chemotherapy separated by 96 h. Each pulse consisted of two doses of cytarabine and a single dose of mitoxantrone. Amifostine was administered three times a week after the second pulse of chemotherapy until treatment outcome became known. The first paper described the outcome of treatment while the second described the relationship of treatment outcome to the pretherapy characteristics of the leukemia. This paper describes the changes in the leukemia cells which occur during remission induction therapy. While only a limited number of specimens were available for each post treatment study, the studies demonstrated a profound fall in blood counts, BM cellularity, and telomerase activity in leukemia cells after pulse # 1 of treatment. This fall was usually accompanied by a coordinate rise in IL6, TNFα, and IL1β transcripts within the AML cells which survived chemotherapy. High levels of telomerase activity in the day 5 marrow was correlated with high levels of IL1β transcripts which in turn were associated with treatment failure ascribable to resistant disease.",
author = "E. Devemy and Biaoru Li and M. Tao and E. Horvath and H. Chopra and L. Fisher and J. Nayini and S. Creech and P. Venugopal and J. Yang and C. Kaspar and Hsu, {W. T.} and Preisler, {H. D.}",
year = "2001",
month = "1",
day = "1",
doi = "10.1016/S0145-2126(01)00032-7",
language = "English (US)",
volume = "25",
pages = "783--791",
journal = "Leukemia Research",
issn = "0145-2126",
publisher = "Elsevier Limited",
number = "9",

}

TY - JOUR

T1 - Poor prognosis acute myelogenous leukemia

T2 - 3 - Biological and molecular biological changes during remission induction therapy

AU - Devemy, E.

AU - Li, Biaoru

AU - Tao, M.

AU - Horvath, E.

AU - Chopra, H.

AU - Fisher, L.

AU - Nayini, J.

AU - Creech, S.

AU - Venugopal, P.

AU - Yang, J.

AU - Kaspar, C.

AU - Hsu, W. T.

AU - Preisler, H. D.

PY - 2001/1/1

Y1 - 2001/1/1

N2 - This is the third paper in a series which describes a new remission induction regimen for patients with 'poor prognosis' acute myelogenous leukemia (AML). Twenty-four patients were treated with two one day pulses of chemotherapy separated by 96 h. Each pulse consisted of two doses of cytarabine and a single dose of mitoxantrone. Amifostine was administered three times a week after the second pulse of chemotherapy until treatment outcome became known. The first paper described the outcome of treatment while the second described the relationship of treatment outcome to the pretherapy characteristics of the leukemia. This paper describes the changes in the leukemia cells which occur during remission induction therapy. While only a limited number of specimens were available for each post treatment study, the studies demonstrated a profound fall in blood counts, BM cellularity, and telomerase activity in leukemia cells after pulse # 1 of treatment. This fall was usually accompanied by a coordinate rise in IL6, TNFα, and IL1β transcripts within the AML cells which survived chemotherapy. High levels of telomerase activity in the day 5 marrow was correlated with high levels of IL1β transcripts which in turn were associated with treatment failure ascribable to resistant disease.

AB - This is the third paper in a series which describes a new remission induction regimen for patients with 'poor prognosis' acute myelogenous leukemia (AML). Twenty-four patients were treated with two one day pulses of chemotherapy separated by 96 h. Each pulse consisted of two doses of cytarabine and a single dose of mitoxantrone. Amifostine was administered three times a week after the second pulse of chemotherapy until treatment outcome became known. The first paper described the outcome of treatment while the second described the relationship of treatment outcome to the pretherapy characteristics of the leukemia. This paper describes the changes in the leukemia cells which occur during remission induction therapy. While only a limited number of specimens were available for each post treatment study, the studies demonstrated a profound fall in blood counts, BM cellularity, and telomerase activity in leukemia cells after pulse # 1 of treatment. This fall was usually accompanied by a coordinate rise in IL6, TNFα, and IL1β transcripts within the AML cells which survived chemotherapy. High levels of telomerase activity in the day 5 marrow was correlated with high levels of IL1β transcripts which in turn were associated with treatment failure ascribable to resistant disease.

UR - http://www.scopus.com/inward/record.url?scp=0034903706&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034903706&partnerID=8YFLogxK

U2 - 10.1016/S0145-2126(01)00032-7

DO - 10.1016/S0145-2126(01)00032-7

M3 - Article

VL - 25

SP - 783

EP - 791

JO - Leukemia Research

JF - Leukemia Research

SN - 0145-2126

IS - 9

ER -